Open Access. Powered by Scholars. Published by Universities.®

Immunoprophylaxis and Therapy Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 2 of 2

Full-Text Articles in Immunoprophylaxis and Therapy

Nanofabrication For Precision Vaccinology, Karen Zagorski Dec 2022

Nanofabrication For Precision Vaccinology, Karen Zagorski

Theses & Dissertations

Vaccines are among the most effective and safe therapeutics known to mankind. Historically the approach to the creation of new vaccines has been dominated by empirical research, trial, and error. This thesis focuses on the more modern, rational approaches to vaccinology based on the current understanding of the inner workings of the immune system. We used nanotechnology for the generation of novel immunogens, addressed several challenges, and characterized the immune responses.

The preparation, characterization, and troubleshooting of several vaccines against dimeric amyloid beta are covered in chapters 4-6. Despite being ultimately unsuccessful, this part provided a deeper understanding of the …


Combinatorial Administration Of Synthetic Tlr4 Agonist Ini-2002 And Novel Mincle Agonist Um-1098 Delivered Via A-Snps Results In Synergistic Il-1Β Production In Human Primary Cells And Enhances Th1 And Th17 Responses In Vivo, Grace D. Jones, Asia Marie Stephanie Riel, Alexander Riffey, Cassandra Buhl Jan 2022

Combinatorial Administration Of Synthetic Tlr4 Agonist Ini-2002 And Novel Mincle Agonist Um-1098 Delivered Via A-Snps Results In Synergistic Il-1Β Production In Human Primary Cells And Enhances Th1 And Th17 Responses In Vivo, Grace D. Jones, Asia Marie Stephanie Riel, Alexander Riffey, Cassandra Buhl

Graduate Student Theses, Dissertations, & Professional Papers

Tuberculosis (TB) kills more people each year than any infectious disease worldwide with recent exception of SARS-CoV-2. Though the Bacille Calmette Guerin (BCG) vaccine confers protection against severe extrapulmonary forms of TB, there is no licensed vaccine for the prevention of pulmonary tuberculosis. The strongest correlate of protection against pulmonary tuberculosis is Th1/Th17 biased cell mediated immunity. Several candidates for TB vaccine adjuvants have shown Th1/Th17 polarizing capacity in clinical trials including Mincle agonist trehalose dibehenate (TDB) and TLR4 agonist monophosphoryl lipid A (MPL). Furthermore, combinatorial administration of MPL and TDB formulated in dimethyldioctadecylammonium (DDA) liposomes has been previously reported …